Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Ultraviolet-A and riboflavin Clear all

Conditions: Keratoconus, Corneal Ectasia
Interventions: KXL System (15 mW/cm2), KXL System (30 mW/cm2), KXL System (45 mW/cm2), riboflavin ophthalmic solution; Device · Drug
Lead sponsor: American-European Congress of Ophthalmic Surgery; Network
Eligibility: 12 Years and older
Enrollment: 1,721 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 71 more

Conditions: Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions: Riboflavin; Drug
Lead sponsor: Joseph B. Ciolino, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fruste Keratoconus, Risk of Ectasia
Interventions: Corneal Cross-Linking, Riboflavin; Device · Drug
Lead sponsor: Cxlusa; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Scottsdale, Arizona • San Diego, California • Miami, Florida + 5 more

Conditions: Keratoconus
Interventions: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment; Combination Product
Lead sponsor: Epion Therapeutics; Industry
Eligibility: 8 Years to 45 Years
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 12
States / cities: Scottsdale, Arizona • Tucson, Arizona • Murrieta, California + 9 more

Conditions: Down Syndrome (DS), Keratoconus, Pellucid Marginal Degeneration, Forme Fruste Keratoconus (FFK)
Interventions: Epi-ON corneal cross-linking (CXL); Combination Product
Lead sponsor: Woolfson Eye Institute; Other
Eligibility: 8 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more

Conditions: Keratolysis
Interventions: Riboflavin, Dextran, UVA Light Source; Drug · Device
Lead sponsor: Joseph B. Ciolino, MD; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 13
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 10 more

Conditions: Keratoconus
Interventions: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment; Combination Product
Lead sponsor: Epion Therapeutics; Industry
Eligibility: 8 Years to 45 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 13
States / cities: Rowland Heights, California • San Francisco, California • Miami, Florida + 10 more

Conditions: Keratoconus
Interventions: Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light, Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light; Drug
Lead sponsor: Joseph B. Ciolino, MD; Other
Eligibility: 18 Years to 50 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Keratoconus, Corneal Ectasia
Interventions: Riboflavin 0.1% ophthalmic solution and pulsed light, Riboflavin 0.1% ophthalmic solution and non-pulsed light; Combination Product
Lead sponsor: Price Vision Group; Industry
Eligibility: 10 Years to 90 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Focus of Study: Radiolabel Recovery and Survival of RBCs
Interventions: Mirasol System for Whole Blood; Device
Lead sponsor: Terumo BCTbio; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Cincinnati, Ohio • Seattle, Washington

Conditions: Keratoconus
Interventions: Theralight crosslinking and Riboflavin; Other
Lead sponsor: Cxlusa; Industry
Eligibility: 8 Years and older
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 6
States / cities: Miami, Florida • Atlanta, Georgia • Rockville, Maryland + 3 more

Conditions: Infectious Keratitis
Interventions: Ultraviolet-A and riboflavin; Other
Lead sponsor: Cxlusa; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: Scottsdale, Arizona • West Hills, California • Littleton, Colorado + 3 more

Conditions: Keratoconus, Ectasia of Cornea, Pellucid Marginal Corneal Degeneration, Forme Fruste Keratoconus (FFK)
Interventions: Epi-ON corneal cross-linking; Combination Product
Lead sponsor: Woolfson Eye Institute; Other
Eligibility: 8 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more

Conditions: Keratoconus, Ectasia
Interventions: UVA Light with irradiance exposure of 9 mW/cm2, Riboflavin 0.1% ophthalmic solution; Device · Drug
Lead sponsor: Stephen Trokel; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Keratoconus
Interventions: Crosslinking using UV light of two different fluence rates; Device
Lead sponsor: McNeel Eye Center; Industry
Eligibility: 15 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Boise, Idaho

Search by objective public record fields.

Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

Combined CXL//UV and PRK or LASIK in Forme Fruste Keratoconus or Eyes With Potential Risk of Ectasia

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients

Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia

Inactivation of Whole Blood With Mirasol

CXL-04 A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases

Higher Irradiance in Keratoconus Ectasia

McNeel Eye Center Corneal Crosslinking Study